Romosozumab versus denosumab in long‐term users of glucocorticoids: A pilot randomized controlled trial
Journal of Internal Medicine · 2024
DOI: 10.1111/joim.20017 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Internal Medicine, 2024. Verfasst von Chi Chiu Mok und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Tuen Mun Hospital, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Denosumab, Bone Density, Glucocorticoids, Bone Density Conservation Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Health and Medical Research Fund, Health Bureau, Hong Kong.
Abstract (Originalsprache)
Objective
To compare the efficacy of romosozumab (ROMO) and denosumab (DEN) in prevalent long‐term glucocorticoid (GC) users.
Methods
Adult patients receiving oral prednisolone (≥5 mg/day) with high risk of fracture were randomized to receive subcutaneous ROMO (210 mg monthly) or DEN (60 mg 6‐monthly) for 12 months, followed by DEN for two more doses. The primary end point was the change in spine bone mineral density (BMD) from Months 0 to 12. Secondary end points included changes in BMD of the spine/hip/femoral neck and bone turnover markers at various time points and adverse events.
Results
Seventy patients (age 62.6 ± 9.1 years; 96% women; median prednisolone dose 5.0 mg/day; duration of therapy 10.7 ± 7.4 years) were enrolled, and 63 completed the study. At Month 12, the spine BMD increased significantly in both ROMO (+7.3% ± 4.5%; p < 0.001) and DEN (+2.3% ± 3.1%; p < 0.001) groups. The absolute spine BMD gain from Months 0 to 12 was significantly greater in ROMO‐treated patients ( p < 0.001). Although the total hip BMD at Month 12 also increased significantly in the ROMO (+1.6% ± 3.3%; p = 0.01) and DEN groups (+1.6% ± 2.6%; p = 0.003), the absolute BMD gain was not significantly different between the groups. At Month 24, the spine BMD continued to increase in both the ROMO (+9.7% ± 4.8%; p < 0.001) and DEN group (+3.0% ± 3.0%; p < 0.001) compared to baseline, and the absolute BMD gain remained significantly greater in ROMO‐treated patients. The total hip BMD continued to increase in both groups (ROMO +2.9% ± 3.7%; p < 0.001; DEN +2.2% ± 3.4%; p = 0.001), but the changes from baseline were similar. Injection site reaction was more frequently reported in ROMO‐treated patients.
Conclusion
ROMO was superior to DEN in raising the spine BMD at Month 12 in chronic GC users. After switching to DEN, ROMO‐treated patients continued to gain spine BMD to a greater extent than DEN until Month 24.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Tuen Mun Hospital, Hong Kong SAR, China.
- Department of Pathology, Queen Elizabeth Hospital, London, UK.
- Department of Medicine, School of Clinical Medicine, University of Hong Kong, Hong Kong SAR, China.
- Department of Nuclear Medicine, Tuen Mun Hospital, Hong Kong SAR, China.
ORCID-Profile: Chi Chiu Mok
Förderung
- Health and Medical Research Fund, Health Bureau, Hong Kong
Zitieren
APA
Mok, C. C., Chan, K. L., Tse, S. M., Chen, S. P. L., Tan, K. C. B., & Ma, W. H. (2024). Romosozumab versus denosumab in long‐term users of glucocorticoids: A pilot randomized controlled trial. Journal of Internal Medicine. https://doi.org/10.1111/joim.20017
Vancouver
Mok CC, Chan KL, Tse SM, Chen SPL, Tan KCB, Ma WH. Romosozumab versus denosumab in long‐term users of glucocorticoids: A pilot randomized controlled trial. Journal of Internal Medicine. 2024. doi:10.1111/joim.20017
BibTeX
@article{Mok2024,
author = {Mok, Chi Chiu and Chan, Kar Li and Tse, Sau Mei and Chen, Sammy Pak Lam and Tan, Kathryn Choon Beng and Ma, Wai Han},
title = {Romosozumab versus denosumab in long‐term users of glucocorticoids: A pilot randomized controlled trial},
journal = {Journal of Internal Medicine},
year = {2024},
doi = {10.1111/joim.20017}
}
EUVIMED